Across TCGA pan-cancer cohorts, BCORP1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BCORP1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where BCORP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BCORP1 is over-expressed in tumor, although a few such as PRAD and LUSC show the opposite, repressed pattern.

KIRC, CHOL, and PRAD are the cancer types where BCORP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCORP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.152	<.001	8	view →
CHOL	All	II,III,IV	+1.204	.013	3	view →
PRAD	All	All	−0.077	.006	2	view →
LUSC	Male	II,III,IV	−0.100	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: BCORP1 RNA expression & survival · all BCORP1 data types